These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 28757264)
1. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. Patel YA; Imperial JC; Muir AJ; Anstee QM; DeBrota D; Dimick-Santos L; Filozof C; Mehta R; Sanyal AJ; Schabel E; Neuschwander-Tetri BA; Miller V; Gastroenterology; 2017 Sep; 153(3):621-625.e7. PubMed ID: 28757264 [No Abstract] [Full Text] [Related]
2. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Noureddin M; Chan JL; Barradas K; Dimick-Santos L; Schabel E; Omokaro SO; Anania FA; Myers RP; Miller V; Sanyal AJ; Chalasani N; Gastroenterology; 2020 Aug; 159(2):422-427.e1. PubMed ID: 32353369 [No Abstract] [Full Text] [Related]
3. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Spengler EK; Loomba R Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858 [TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development. Alkhouri N Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024 [No Abstract] [Full Text] [Related]
6. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected? Michel M; Schattenberg JM Expert Opin Investig Drugs; 2020 Feb; 29(2):93-97. PubMed ID: 31933385 [No Abstract] [Full Text] [Related]
8. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814 [TBL] [Abstract][Full Text] [Related]
9. How to Approach a Patient With Nonalcoholic Fatty Liver Disease. Tilg H Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352 [No Abstract] [Full Text] [Related]
10. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). Fan JG; Wei L; Zhuang H; J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584 [No Abstract] [Full Text] [Related]
11. Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality. Athyros VG; Doumas M Curr Vasc Pharmacol; 2018; 16(3):206-208. PubMed ID: 29598814 [No Abstract] [Full Text] [Related]
12. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572 [TBL] [Abstract][Full Text] [Related]
13. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Kanwar P; Kowdley KV Clin Liver Dis; 2016 May; 20(2):225-43. PubMed ID: 27063266 [TBL] [Abstract][Full Text] [Related]